Liposomal anthracycline chemotherapy in the treatment of AIDS-related Kaposi's sarcoma

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The treatments employed for Kaposi's sarcoma in patients with acquired immunodeficiency syndrome (AIDS-KS) have been limited in their usefulness by toxicities and underlying immunodeficiency in this patient population. Recently, liposomal anthracycline chemotherapeutic agents have been developed and used in AIDS-KS. Liposomal encapsulation may provide greater concentration of anthracycline in the KS lesions when compared with standard anthracycline administration. Also, the favorable pharmacokinetic parameters of the encapsulated formulations-longer half-life, greater area under the concentration-time curve (AUC), and slower clearance-may allow the lesions to he exposed to these cytotoxic agents for longer periods of time. Phase II and III studies testing the safety and efficacy of liposomal anthracyclines demonstrate that they are at least as efficacious as standard regimens, with a better safety profile.

Original languageEnglish (US)
Pages (from-to)21-32
Number of pages12
JournalOncology
Volume11
Issue number10 SUPPL. 11
StatePublished - 1997
Externally publishedYes

Fingerprint

Anthracyclines
Drug Therapy
Acquired Immunodeficiency Syndrome
Safety
Kaposi's Sarcoma
Cytotoxins
Therapeutics
Half-Life
Pharmacokinetics
AIDS-related Kaposi sarcoma
Population

ASJC Scopus subject areas

  • Oncology

Cite this

Liposomal anthracycline chemotherapy in the treatment of AIDS-related Kaposi's sarcoma. / Northfelt, Donald W.

In: Oncology, Vol. 11, No. 10 SUPPL. 11, 1997, p. 21-32.

Research output: Contribution to journalArticle

@article{9a08d41256ed41fda0f413da67b2be2d,
title = "Liposomal anthracycline chemotherapy in the treatment of AIDS-related Kaposi's sarcoma",
abstract = "The treatments employed for Kaposi's sarcoma in patients with acquired immunodeficiency syndrome (AIDS-KS) have been limited in their usefulness by toxicities and underlying immunodeficiency in this patient population. Recently, liposomal anthracycline chemotherapeutic agents have been developed and used in AIDS-KS. Liposomal encapsulation may provide greater concentration of anthracycline in the KS lesions when compared with standard anthracycline administration. Also, the favorable pharmacokinetic parameters of the encapsulated formulations-longer half-life, greater area under the concentration-time curve (AUC), and slower clearance-may allow the lesions to he exposed to these cytotoxic agents for longer periods of time. Phase II and III studies testing the safety and efficacy of liposomal anthracyclines demonstrate that they are at least as efficacious as standard regimens, with a better safety profile.",
author = "Northfelt, {Donald W}",
year = "1997",
language = "English (US)",
volume = "11",
pages = "21--32",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "10 SUPPL. 11",

}

TY - JOUR

T1 - Liposomal anthracycline chemotherapy in the treatment of AIDS-related Kaposi's sarcoma

AU - Northfelt, Donald W

PY - 1997

Y1 - 1997

N2 - The treatments employed for Kaposi's sarcoma in patients with acquired immunodeficiency syndrome (AIDS-KS) have been limited in their usefulness by toxicities and underlying immunodeficiency in this patient population. Recently, liposomal anthracycline chemotherapeutic agents have been developed and used in AIDS-KS. Liposomal encapsulation may provide greater concentration of anthracycline in the KS lesions when compared with standard anthracycline administration. Also, the favorable pharmacokinetic parameters of the encapsulated formulations-longer half-life, greater area under the concentration-time curve (AUC), and slower clearance-may allow the lesions to he exposed to these cytotoxic agents for longer periods of time. Phase II and III studies testing the safety and efficacy of liposomal anthracyclines demonstrate that they are at least as efficacious as standard regimens, with a better safety profile.

AB - The treatments employed for Kaposi's sarcoma in patients with acquired immunodeficiency syndrome (AIDS-KS) have been limited in their usefulness by toxicities and underlying immunodeficiency in this patient population. Recently, liposomal anthracycline chemotherapeutic agents have been developed and used in AIDS-KS. Liposomal encapsulation may provide greater concentration of anthracycline in the KS lesions when compared with standard anthracycline administration. Also, the favorable pharmacokinetic parameters of the encapsulated formulations-longer half-life, greater area under the concentration-time curve (AUC), and slower clearance-may allow the lesions to he exposed to these cytotoxic agents for longer periods of time. Phase II and III studies testing the safety and efficacy of liposomal anthracyclines demonstrate that they are at least as efficacious as standard regimens, with a better safety profile.

UR - http://www.scopus.com/inward/record.url?scp=0030731376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030731376&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030731376

VL - 11

SP - 21

EP - 32

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 10 SUPPL. 11

ER -